Personalized Medicine in Oncology
Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Témata: | |
| On-line přístup: | ONIX_20220224_9783036528205_71 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869522202676690944 |
|---|---|
| collection | Directory of Open Access Books |
| description | Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first “site-agnostic” drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic “signatures” that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment. |
| format | Online |
| id | doab-20.500.12854ir-78773 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-787732024-03-30T23:23:00Z Personalized Medicine in Oncology VanderWalde, Ari patient-derived tumor xenograft (PDX) anti-cancer drug development immunodeficient mice precision medicine molecular profiling immunohistochemistry next-generation sequencing targeted therapy molecular oncology biomarkers molecular imaging non-small cell lung cancer proliferation cancer stem cells circulating tumour cells personalised treatment renal cell carcinoma clear cell VEGF immunotherapy PD-L1 immune checkpoint inhibitors immune checkpoint blockade tyrosine-kinase inhibitors integrin-linked kinase (ILK) ovarian cancer sgRNA gene expression microarray xenograft MTB cancer oncology practice community setting CGP pancreatic cancer FOLFIRINOX chemotherapy gender cholangiocarcinoma biliary tract cancer prognosis neutrophils BRCA1 BRCA2 PALB2 homologous recombination repair colorectal cancer heme oxygenase-1 endothelin-1 endothelin con-verting enzyme-1 bosentan precision oncology tumor-agnostic indications solid tumors tumor markers FDA-approved therapeutics n/a thema EDItEUR::M Medicine and Nursing Nowhere is the explosion in comprehensive genomic testing more evident than in oncology. Multiple consensus guidelines now recommend molecular testing as the standard of care for most metastatic tumors. To aid in the advancement of this rapidly changing field, we intend this Special Issue of JPM to focus on technical developments in the genomic profiling of cancer, detail promising somatic alterations that either are, or have a high likelihood of being, relevant in the near future, and to address issues related to the pricing and value of these tests.The last few years have seen the cost of molecular testing decrease by orders of magnitude. In 2018, we saw the first “site-agnostic” drug approvals in cancer (for microsatellite unstable cancer (PD-1 inhibitors) and NTRK-fusions (TRK inhibitors)). Research on targetable mutations, determination of genetic “signatures” that can use multiple individual genes/pathways, development of targeted therapy, and insight into the value of new technology remains at the cutting edge of research in this field. We are soliciting papers that present new technologies to assess predictive biomarkers in cancer, original research (pre-clinical or clinical) that demonstrates promise for particular targeted therapies in cancer, and articles that explore the clinical and financial impacts of this paradigmatic shift in cancer diagnostics and treatment. 2022-02-24T10:35:59Z 2022-02-24T10:35:59Z 2022 book ONIX_20220224_9783036528205_71 9783036528205 9783036528212 https://directory.doabooks.org/handle/20.500.12854/78773 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4866 https://mdpi.com/books/pdfview/book/4866 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-2820-5 10.3390/books978-3-0365-2820-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036528205 9783036528212 174 Basel open access |
| spellingShingle | patient-derived tumor xenograft (PDX) anti-cancer drug development immunodeficient mice precision medicine molecular profiling immunohistochemistry next-generation sequencing targeted therapy molecular oncology biomarkers molecular imaging non-small cell lung cancer proliferation cancer stem cells circulating tumour cells personalised treatment renal cell carcinoma clear cell VEGF immunotherapy PD-L1 immune checkpoint inhibitors immune checkpoint blockade tyrosine-kinase inhibitors integrin-linked kinase (ILK) ovarian cancer sgRNA gene expression microarray xenograft MTB cancer oncology practice community setting CGP pancreatic cancer FOLFIRINOX chemotherapy gender cholangiocarcinoma biliary tract cancer prognosis neutrophils BRCA1 BRCA2 PALB2 homologous recombination repair colorectal cancer heme oxygenase-1 endothelin-1 endothelin con-verting enzyme-1 bosentan precision oncology tumor-agnostic indications solid tumors tumor markers FDA-approved therapeutics n/a thema EDItEUR::M Medicine and Nursing Personalized Medicine in Oncology |
| title | Personalized Medicine in Oncology |
| title_full | Personalized Medicine in Oncology |
| title_fullStr | Personalized Medicine in Oncology |
| title_full_unstemmed | Personalized Medicine in Oncology |
| title_short | Personalized Medicine in Oncology |
| title_sort | personalized medicine in oncology |
| topic | patient-derived tumor xenograft (PDX) anti-cancer drug development immunodeficient mice precision medicine molecular profiling immunohistochemistry next-generation sequencing targeted therapy molecular oncology biomarkers molecular imaging non-small cell lung cancer proliferation cancer stem cells circulating tumour cells personalised treatment renal cell carcinoma clear cell VEGF immunotherapy PD-L1 immune checkpoint inhibitors immune checkpoint blockade tyrosine-kinase inhibitors integrin-linked kinase (ILK) ovarian cancer sgRNA gene expression microarray xenograft MTB cancer oncology practice community setting CGP pancreatic cancer FOLFIRINOX chemotherapy gender cholangiocarcinoma biliary tract cancer prognosis neutrophils BRCA1 BRCA2 PALB2 homologous recombination repair colorectal cancer heme oxygenase-1 endothelin-1 endothelin con-verting enzyme-1 bosentan precision oncology tumor-agnostic indications solid tumors tumor markers FDA-approved therapeutics n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | patient-derived tumor xenograft (PDX) anti-cancer drug development immunodeficient mice precision medicine molecular profiling immunohistochemistry next-generation sequencing targeted therapy molecular oncology biomarkers molecular imaging non-small cell lung cancer proliferation cancer stem cells circulating tumour cells personalised treatment renal cell carcinoma clear cell VEGF immunotherapy PD-L1 immune checkpoint inhibitors immune checkpoint blockade tyrosine-kinase inhibitors integrin-linked kinase (ILK) ovarian cancer sgRNA gene expression microarray xenograft MTB cancer oncology practice community setting CGP pancreatic cancer FOLFIRINOX chemotherapy gender cholangiocarcinoma biliary tract cancer prognosis neutrophils BRCA1 BRCA2 PALB2 homologous recombination repair colorectal cancer heme oxygenase-1 endothelin-1 endothelin con-verting enzyme-1 bosentan precision oncology tumor-agnostic indications solid tumors tumor markers FDA-approved therapeutics n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220224_9783036528205_71 |